Rabies, being a major zoonotic disease, significantly impacts global public health. It is invariably fatal once clinical signs are apparent. The majority of human rabies deaths occur in developing countries. India alone reports more than 50% of the global rabies deaths. Although it is a vaccine-preventable disease, effective rabies prevention in humans with category III bites requires the combined administration of rabies immunoglobulin (RIG) and vaccine. Cell culture rabies vaccines have become widely available in developing countries, virtually replacing the inferior and unsafe nerve tissue vaccines. Limitations inherent to the conventional RIG of either equine or human origin have prompted scientists to look for monoclonal antibody-based human RIG as an alternative. Fully human monoclonal antibodies have been found to be safer and equally efficacious than conventional RIG when tested in mice and hamsters. In this chapter, rabies epidemiology, reservoir control measures, post-exposure prophylaxis of human rabies, and combination therapy for rabies are discussed. Novel human monoclonal antibodies, their production, and the significance of plants as expression platforms are emphasized.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amengual B, Whitby JE, King A, Cobo JS, Bourhy H (1997) Evolution of European bat lyssaviruses. J Gen Virol 78:2319–2328
Arya SC (1991) Acquisition of spongiform encephalopathies in India through sheep-brain rabies vaccination. Indian J Pediatr 58:563–565
Aubert MF, Masson E, Artois M, Barrat J (1994) Oral wildlife rabies vaccination field trials in Europe, with recent emphasis on France. Curr Top Microbiol Immunol 187:219–243
Badrane H, Tordo N (2001) Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. J Virol 75:8096–8104
Badrane H, Bahloul C, Perrin P, Tordo N (2001) Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 75:3268–3276
Baer GM, Lentz TL (1991) Rabies pathogenesis in the central nervous system. In: Baer GM (ed) The natural history of rabies. CRC Press, Boca Raton, pp 105–120
Bahloul C, Jacob Y, Tordo N, Perrin P (1998) DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine 16:417–425
Bahloul C, Ahmed SB, B’Chir BI, Kharmachi H, Hayouni el A, Dellagi K (2003) Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine. Vaccine 22:177–184
Bahloul C, Taieb D, Diouani MF, Ahmed SB, Chtourou Y, B’Chir BI, Kharmachi H, Dellagi K (2006) Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions. Vaccine 24:1063–1072
Bakker H, Bardor M, Molthoff JW, Gomord V, Elbers I, Stevens LH, Jordi W, Lommen A, Faye L, Lerouge P, Bosch D (2001) Galactose-extended glycans of antibodies produced by transgenic plants. Proc Natl Acad Sci U S A 98:2899–2904
Balthazard M, Bhamanyar M, Ghodssi M, Sabeti A, Gajdusek C, Rouzbehi E (1955) Essai pratique du serum antirabique chez les mordus par loups enrages. Bull World Health Organ 13:747–772
Barth R, Gruschkau H, Bijok U, Hilfenhaus J, Hinz J, Milcke L, Moser H, Jaeger O, Ronneberger H, Weinmann E (1984) A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PCEC-vaccine by laboratory tests. J Biol Stand 12:29–46
Belotto A, Leanes LF, Schneider MC, Tamayo H, Correa E (2005) Overview of rabies in the Americas. Virus Res 111:5–12
Benmansour A, Leblois H, Coulon P, Tuffereau C, Gaudin Y, Flamand A, Lafay F (1991) Antigenicity of rabies virus glycoprotein. J Virol 65:4198–4203
Bhatia R, Ichhpujani RL, Madhusudana SN, Hemachudha T (2004) Rabies in South and Southeast Asia. In: Program and abstracts of the WHO Expert Consultation on Rabies, Geneva
Biswas S, Reddy GS, Srinivasan VA, Rangarajan PN (2001) Preexposure efficacy of a novel combination DNA and inactivated rabies virus vaccine. Hum Gene Ther 12:1917–1922
Blancou J (1988) Ecology and epidemiology of fox rabies. Rev Infect Dis 10 [Suppl 4]:S606–S609
Bogel K, Motschwiller E (1986) Incidence of rabies and post-exposure treatment in developing countries. Bull World Health Organ 64:883–887
Bourhy H, Kissi B, Lafon M, Sacramento D, Tordo N (1992) Antigenic and molecular characterization of bat rabies virus in Europe. J Clin Microbiol 30:2419–2426
Bourhy H, Kissi B, Tordo N (1993) Molecular diversity of the Lyssavirus genus. Virology 194:70–81
Bregenholt S, Haurum J (2004) Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opin Biol Ther 4:387–396
Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2:52–62
Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, Tongswas S, Wasi C (2000) Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 78:693–698
Brookes SM, Parsons G, Johnson N, McElhinney LM, Fooks AR (2005) Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine 23:4101–4109
Carroll WL, Thielemans K, Dilley J, Levy R (1986) Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 89:61–72
Casadevall A (2002) Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis 8:833–841
Center for Biologics Evaluation and Research (1995) Guidance for industry: considerations for plasmid DNA vaccines for infectious disease indications. http://www.fda.gov/cber/gdlns/plasdnavac.pdf. Cited 18 May 2007
Centers for Disease Control and Prevention (1999) Human rabies prevention—United States, 1999. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 48:1–21
Centers for Disease Control (2004) Manufacturer’s recall of human rabies vaccine. MMWR Dispatch 53:287–289
Champion JM, Kean RB, Rupprecht CE, Notkins AL, Koprowski H, Dietzschold B, Hooper DC (2000) The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods 235:81–90
Cheung SC, Dietzschold B, Koprowski H, Notkins AL, Rando RF (1992) A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus. J Virol 66:6714–6720
Childs JE, Curns AT, Dey ME, Real LA, Feinstein L, Bjornstad ON, Krebs JW (2000) Predicting the local dynamics of epizootic rabies among raccoons in the United States. Proc Natl Acad Sci U S A 97:13666–13671
Chin J (2000) Control of communicable diseases manual. APHA, Washington, DC
Chutivongse S, Wilde H, Supich C, Baer GM, Fishbein DB (1990) Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 335:896–898
Chutivongse S, Wilde H, Fishbein DB, Baer GM, Hemachudha T (1991) One-year study of the 2–1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 9:573–576
Cleaveland S, Kaare M, Tiringa P, Mlengeya T, Barrat J (2003) A dog rabies vaccination campaign in rural Africa: impact on the incidence of dog rabies and human dog-bite injuries. Vaccine 21:1965–1973
Cliquet F, Aubert M, Sagne L (1998) Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 212:79–87
Coleman PG, Fevre EM, Cleaveland S (2004) Estimating the public health impact of rabies. Emerg Infect Dis 10:140–142
Corn JL, Mendez JR, Catalan EE (2003) Evaluation of baits for delivery of oral rabies vaccine to dogs in Guatemala. Am J Trop Med Hyg 69:155–158
Cox JH, Dietzschold B, Schneider LG (1977) Rabies virus glycoprotein. II. Biological and serological characterization. Infect Immun 16:754–759
Daniell H, Streatfield SJ, Wycoff K (2001) Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci 6:219–226
David D, Yakobson BA, Gershkovich L, Gayer S (2004) Tracing the regional source of rabies infection in an Israeli dog by viral analysis. Vet Rec 155:496–497
de Kruif J, Bakker AB, Marissen WE, Kramer RA, Throsby M, Rupprecht CE, Goudsmit J (2007) A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 58:359–368
Dean DJ, Baer GM, Thompson WR (1963) Studies on the local treatment of rabies-infected wounds. Bull World Health Organ 28:477–486
Dietzschold B, Schnell MJ (2002) New approaches to the development of live attenuated rabies vaccines. Hybrid Hybridomics 21:129–134
Dietzschold B, Tollis M, Lafon M, Wunner WH, Koprowski H (1987) Mechanisms of rabies virus neutralization by glycoprotein-specific monoclonal antibodies. Virology 161:29–36
Dietzschold B, Gore M, Casali P, Ueki Y, Rupprecht CE, Notkins AL, Koprowski H (1990) Biological characterization of human monoclonal antibodies to rabies virus. J Virol 64: 3087–3090
Dietzschold B, Kao M, Zheng YM, Chen ZY, Maul G, Fu ZF, Rupprecht CE, Koprowski H (1992) Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci U S A 89:7252–7256
Dietzschold B, Faber M, Schnell MJ (2003) New approaches to the prevention and eradication of rabies. Expert Rev Vaccines 2:399–406
Dreesen DW, Fishbein DB, Kemp DT, Brown J (1989) Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. Vaccine 7:397–400
Enssle K, Kurrle R, Kohler R, Muller H, Kanzy EJ, Hilfenhaus J, Seiler FR (1991) A rabies-specific human monoclonal antibody that protects mice against lethal rabies. Hybridoma 10:547–556
Ertl HC (2005) Immunological insights from genetic vaccines. Virus Res 111:89–92
Ertl HC, Xiang ZQ (1996) Genetic immunization. Viral Immunol 9:1–9
Estrada R, Vos A, De Leon R, Mueller T (2001) Field trial with oral vaccination of dogs against rabies in the Philippines. BMC Infect Dis 1:23
Farrugia A, Poulis P (2001) Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfus Med 11:63–74
Fu ZF (1997) Rabies and rabies research: past, present and future. Vaccine 15 Suppl:S20–S24
Fuenzalida E, Palacios R (1955) An improved method for preparation of rabies vaccine [in Spanish]. Biol Inst Bacteriol Chile 8:3–10
Funaro A, Horenstein AL, Ghisolfi G, Bussolati B, Bartorelli A, Bussolati G (1999) Identification of a 220-kDa membrane tumor-associated antigen by human anti-UK114 monoclonal antibodies selected from the immunoglobulin repertoire of a cancer patient. Exp Cell Res 247:441–450
Girard LS, Fabis MJ, Bastin M, Courtois D, Petiard V, Koprowski H (2006) Expression of a human anti-rabies virus monoclonal antibody in tobacco cell culture. Biochem Biophys Res Commun 345:602–607
Goudsmit J, Marissen WE, Weldon WC, Niezgoda M, Hanlon CA, Rice AB, Kruif J, Dietzschold B, Bakker AB, Rupprecht CE (2006) Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 193:796–801
Haddad N, Ben Khelifa R, Matter H, Kharmachi H, Aubert MF, Wandeler A, Blancou J (1994) Assay of oral vaccination of dogs against rabies in Tunisia with the vaccinal strain SADBern. Vaccine 12:307–309
Hanlon CA, Niezgoda M, Morrill PA, Rupprecht CE (2001) The incurable wound revisited: progress in human rabies prevention? Vaccine 19:2273–2279
Hassett DE, Whitton JL (1996) DNA immunization. Trends Microbiol 4:307–312
Hattwick MA, Corey L, Creech WB (1976) Clinical use of human globulin immune to rabies virus. J Infect Dis 133 Suppl:A266–272
Haurum J, Bregenholt S (2005) Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle. IDrugs 8:404–409
Hellwig S, Drossard J, Twyman RM, Fischer R (2004) Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 22:1415–1422
Hemachudha T (1989) Rabies. In: Vinken PJ, Bruyn GW, Klawans HL, McKendall RR (eds) Viral disease. Elsevier, Amsterdam, pp 383–404
Hemachudha T (1994) Human rabies: clinical aspects, pathogenesis, and potential therapy. Curr Top Microbiol Immunol 187:121–143
Hemachudha T, Mitrabhakdi E (2000) Rabies. In: Davis LE, Kennedy PGE (eds) Infectious diseases of the nervous system. Butterworth Heinemann, Oxford, pp 401–444
Hemachudha T, Phuapradit P (1997) Rabies. Curr Opin Neurol 10:260–267
Hemachudha T, Phanuphak P, Johnson RT, Griffin DE, Ratanavongsiri J, Siriprasomsup W (1987) Neurologic complications of Semple-type rabies vaccine: clinical and immunologic studies. Neurology 37:550–556
Hemachudha T, Laothamatas J, Rupprecht CE (2002) Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet Neurol 1:101–109
Hiatt A, Cafferkey R, Bowdish K (1989) Production of antibodies in transgenic plants. Nature 342:76–78
Holmes EC, Woelk CH, Kassis R, Bourhy H (2002) Genetic constraints and the adaptive evolution of rabies virus in nature. Virology 292:247–257
Hooper DC, Morimoto K, Bette M, Weihe E, Koprowski H, Dietzschold B (1998) Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol 72:3711–3719
Hooper PT, Lunt RA, Gould AR, Samaratunga H, Hyatt AD, Gleeson LJ, Rodwell BJ, Rupprecht CE, Smith JS, Murray PK (1997) A new lyssavirus—the first endemic rabies-related virus recognized in Australia. Bull Inst Pasteur 95:209–218
Ichhpujani RL, Bhardwaj M, Chhabra M, Datta KK (2001) Rabies in humans in India. In: Dodet B, Meslin FX, Haseltine E (eds) Proceedings of the fourth international symposium on rabies control in Asia. John Libbey Eurotext, London, pp 212–213
Ito M, Itou T, Shoji Y, Sakai T, Ito FH, Arai YT, Takasaki T, Kurane I (2003) Discrimination between dog-related and vampire bat-related rabies viruses in Brazil by strain-specific reverse transcriptase-polymerase chain reaction and restriction fragment length polymorphism analysis. J Clin Virol 26:317–330
Jallet C, Jacob Y, Bahloul C, Drings A, Desmezieres E, Tordo N, Perrin P (1999) Chimeric lyssavirus glycoproteins with increased immunological potential. J Virol 73:225–233
Jenkins SR, Perry BD, Winkler WG (1988) Ecology and epidemiology of raccoon rabies. Rev Infect Dis 10 [Suppl 4]:S620–S625
Jenkins SR, Auslander M, Conti L, Leslie MJ, Sorhage FE, Sun B (2004) Compendium of animal rabies prevention and control, 2004. J Am Vet Med Assoc 224:216–222
Kallel H, Diouani MF, Loukil H, Trabelsi K, Snoussi MA, Majoul S, Rourou S, Dellagi K (2006) Immunogenicity and efficacy of an in-house developed cell-culture derived veterinarian rabies vaccine. Vaccine 24:4856–4862
Khawplod P, Wilde H, Chomchey P, Benjavongkulchai M, Yenmuang W, Chaiyabutr N, Sitprija V (1996) What is an acceptable delay in rabies immune globulin administration when vaccine alone had been given previously? Vaccine 14:389–391
Kilic B, Unal B, Semin S, Konakci SK (2006) An important public health problem: rabies suspected bites and post-exposure prophylaxis in a health district in Turkey. Int J Infect Dis 10:248–254
Kitala PM, McDermott JJ, Kyule MN, Gathuma JM (2000) Community-based active surveillance for rabies in Machakos District, Kenya. Prev Vet Med 44:73–85
Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, Miranda ME, Shaw A, Zinsstag J, Meslin FX (2005) Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83:360–368
Ko K, Tekoah Y, Rudd PM, Harvey DJ, Dwek RA, Spitsin S, Hanlon CA, Rupprecht C, Dietzschold B, Golovkin M, Koprowski H (2003) Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc Natl Acad Sci U S A 100:8013–8018
Koprowski H, Van Der Scheer J, Black J (1950) Use of hyperimmune anti-rabies serum concentrates in experimental rabies. Am J Med 8:412–420
Koprowski H, Wiktor T, Abelseth M (1985) Cross-reactivity and cross-protection: rabies variants and rabies-related viruses. In: Kuwert E, Merieux C, Koprowski H, Bogel K (eds) Rabies in the tropics. Springer-Verlag, Berlin Heidelberg New York, pp 30–39
Kramer RA, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van der Horst M, Bakker AQ, de Jong M, Jongeneelen M, Thijsse S, Backus HH, Rice AB, Weldon WC, Rupprecht CE, Dietzschold B, Bakker AB, de Kruif J (2005) The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol 35:2131–2145
Krebs JW, Mandel EJ, Swerdlow DL, Rupprecht CE (2005) Rabies surveillance in the United States during 2004. J Am Vet Med Assoc 227:1912–1925
Kureishi A, Xu LZ, Wu H, Stiver HG (1992) Rabies in China: recommendations for control. Bull World Health Organ 70:443–450
Kuzmin IV, Hughes GJ, Botvinkin AD, Orciari LA, Rupprecht CE (2005) Phylogenetic relationships of Irkut and West Caucasian bat viruses within the Lyssavirus genus and suggested quantitative criteria based on the N gene sequence for Lyssavirus genotype definition. Virus Res 111:28–43
Lafon M, Edelman L, Bouvet JP, Lafage M, Montchatre E (1990) Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol 71:1689–1696
Lerouge P, Bardor M, Pagny S, Gomord V, Faye L (2000) N-Glycosylation of recombinant pharmaceutical glycoproteins produced in transgenic plants: towards an humanisation of plant N-glycans. Curr Pharm Biotechnol 1:347–354
Liang M, Dubel S, Li D, Queitsch I, Li W, Bautz EK (2001) Baculovirus expression cassette vectors for rapid production of complete human IgG from phage display selected antibody fragments. J Immunol Methods 247:119–130
Libeau G, Lafon M (1984) Production of monoclonal antibodies against the Pasteur (P.V.) strain of rabies virus: problems and results. Dev Biol Stand 57:213–218
Lodmell DL, Ewalt LC (2001) Post-exposure DNA vaccination protects mice against rabies virus. Vaccine 19:2468–2473
Lodmell DL, Ray NB, Parnell MJ, Ewalt LC, Hanlon CA, Shaddock JH, Sanderlin DS, Rupprecht CE (1998) DNA immunization protects nonhuman primates against rabies virus. Nat Med 4:949–952
Lodmell DL, Ray NB, Ulrich JT, Ewalt LC (2000) DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL). Vaccine 18:1059–1066
Lodmell DL, Parnell MJ, Bailey JR, Ewalt LC, Hanlon CA (2001) One-time gene gun or intramuscular rabies DNA vaccination of non-human primates: comparison of neutralizing antibody responses and protection against rabies virus 1 year after vaccination. Vaccine 20:838–844
Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, Hein MB, Lehner T (1998) Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med 4:601–606
MacInnes CD, Smith SM, Tinline RR, Ayers NR, Bachmann P, Ball DG, Calder LA, Crosgrey SJ, Fielding C, Hauschildt P, Honig JM, Johnston DH, Lawson KF, Nunan CP, Pedde MA, Pond B, Stewart RB, Voigt DR (2001) Elimination of rabies from red foxes in eastern Ontario. J Wildl Dis 37:119–132
Marissen WE, Kramer RA, Rice A, Weldon WC, Niezgoda M, Faber M, Slootstra JW, Meloen RH, Clijsters-van der Horst M, Visser TJ, Jongeneelen M, Thijsse S, Throsby M, de Kruif J, Rupprecht CE, Dietzschold B, Goudsmit J, Bakker AB (2005) Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol 79:4672–4678
Martinez L (2000) Global infectious disease surveillance. Int J Infect Dis 4:222–228
Matha IS, Salunke SR (2005) Immunogenicity of purified vero cell rabies vaccine used in the treatment of fox-bite victims in India. Clin Infect Dis 40:611–613
May RM, Anderson RM (1984) Spatial heterogeneity and the design of immunization programs. Math Biosci 72:83–111
Mayen F (2003) Haematophagous bats in Brazil, their role in rabies transmission, impact on public health, livestock industry and alternatives to an indiscriminate reduction of bat population. J Vet Med B Infect Dis Vet Public Health 50:469–472
McKay N, Wallis L (2005) Rabies: a review of UK management. Emerg Med J 22:316–321
Mebatsion T, Weiland F, Conzelmann KK (1999) Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J Virol 73:242–250
Meslin FX, Kaplan MM (1996) General considerations in the production and use of brain-tissue and purified chicken embryo rabies vaccines for human use. In: Meslin FX, Kaplan MM, koprowski H (eds) Laboratory techniques in rabies. WHO, Geneva, pp 221–233
Meslin FX, Fishbein DB, Matter HC (1994) Rationale and prospects for rabies elimination in developing countries. Curr Top Microbiol Immunol 187:1–26
Messenger SL, Smith JS, Rupprecht CE (2002) Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States. Clin Infect Dis 35:738–747
Mitmoonpitak C, Tepsumethanon V, Wilde H (1998) Rabies in Thailand. Epidemiol Infect 120:165–169
Montagnon B, Vincent-Falquet JC, Fanget B (1983) Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine. Promising results. Dev Biol Stand 55:37–42
Morimoto K, Patel M, Corisdeo S, Hooper DC, Fu ZF, Rupprecht CE, Koprowski H, Dietzschold B (1996) Characterization of a unique variant of bat rabies virus responsible for newly emerging human cases in North America. Proc Natl Acad Sci U S A 93:5653–5658
Morimoto K, McGettigan JP, Foley HD, Hooper DC, Dietzschold B, Schnell MJ (2001a) Genetic engineering of live rabies vaccines. Vaccine 19:3543–3551
Morimoto K, Schnell MJ, Pulmanausahakul R, McGettigan JP, Foley HD, Faber M, Hooper DC, Dietzschold B (2001b) High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. J Immunol Methods 252:199–206
Mudur G (2005) Foreign visitors to India are unaware of rabies risk. BMJ 331:255
Muller BH, Lafay F, Demangel C, Perrin P, Tordo N, Flamand A, Lafaye P, Guesdon JL (1997) Phage-displayed and soluble mouse scFv fragments neutralize rabies virus. J Virol Methods 67:221–233
Nadin-Davis SA, Abdel-Malik M, Armstrong J, Wandeler AI (2002) Lyssavirus P gene characterisation provides insights into the phylogeny of the genus and identifies structural similarities and diversity within the encoded phosphoprotein. Virology 298:286–305
Nagarajan T, Mohanasubramanian B, Seshagiri EV, Nagendrakumar SB, Saseendranath MR, Satyanarayana ML, Thiagarajan D, Rangarajan PN, Srinivasan VA (2006a) Molecular epidemiology of rabies virus isolates in India. J Clin Microbiol 44:3218–3224
Nagarajan T, Reddy GS, Mohana Subramanian B, Rajalakshmi S, Thiagarajan D, Tordo N, Jallet C, Srinivasan VA (2006b) A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture. Biologicals 34:21–27
Nel LH, Sabeta CT, von Teichman B, Jaftha JB, Rupprecht CE, Bingham J (2005) Mongoose rabies in southern Africa: a re-evaluation based on molecular epidemiology. Virus Res 109:165–173
Nicholson KG (1996) Cell-culture vaccines for human use: general considerations. In: Meslin FX, Kaplan MM, Koprowski H (eds) Laboratory techniques in rabies. WHO, Geneva, pp 271–279
Nishizono A, Mannen K, Elio-Villa LP, Tanaka S, Li KS, Mifune K, Arca BF, Cabanban A, Martinez B, Rodriguez A, Atienza VC, Camba R, Resontoc N (2002) Genetic analysis of rabies virus isolates in the Philippines. Microbiol Immunol 46:413–417
Owens RJ, Young RJ (1994) The genetic engineering of monoclonal antibodies. J Immunol Methods 168:149–165
Parviz S, Luby S, Wilde H (1998) Postexposure treatment of rabies in Pakistan. Clin Infect Dis 27:751–756
Pasquini S, Deng H, Reddy ST, Giles-Davis W, Ertl HC (1999) The effect of CpG sequences on the B cell response to a viral glycoprotein encoded by a plasmid vector. Gene Ther 6:1448–1455
Patrick GR, O’Rourke KM (1998) Dog and cat bites: epidemiologic analyses suggest different prevention strategies. Public Health Rep 113:252–257
Perera MA, Harischandra PA, Wimalaratne O, Damboragama SN (2000) Feasibility of canine oral rabies vaccination in Sri Lanka—a preliminary report. Ceylon Med J 45:61–64
Perrin P, Madhusudana S, Gontier-Jallet C, Petres S, Tordo N, Merten OW (1995) An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system. Vaccine 13:1244–1250
Perrin P, Jacob Y, Aguilar-Setien A, Loza-Rubio E, Jallet C, Desmezieres E, Aubert M, Cliquet F, Tordo N (1999) Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine 18:479–486
Pinto AR, Reyes-Sandoval A, Ertl HC (2003) Chemokines and TRANCE as genetic adjuvants for a DNA vaccine to rabies virus. Cell Immunol 224:106–113
Plotkin SA (1980) Rabies vaccine prepared in human cell cultures: progress and perspectives. Rev Infect Dis 2:433–448
Plotkin SA, Rupprecht CE, Koprowski H (1999) Rabies vaccine. In: Plotkin SA, Orenstein WA (eds) Vaccines. WB Saunders, Philadelphia, pp 743–766
Prehaud C, Coulon P, LaFay F, Thiers C, Flamand A (1988) Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J Virol 62:1–7
Prosniak M, Faber M, Hanlon CA, Rupprecht CE, Hooper DC, Dietzschold B (2003) Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies. J Infect Dis 188:53–56
Ramanna BC, Reddy GS, Srinivasan VA (1991) An outbreak of rabies in cattle and use of tissue culture rabies vaccine during the outbreak. J Commun Dis 23:283–285
Rath A, Choudhury S, Batra D, Kapre SV, Rupprecht CE, Gupta SK (2005) DNA vaccine for rabies: relevance of the transmembrane domain of the glycoprotein in generating an antibody response. Virus Res 113:143–152
Ray NB, Ewalt LC, Lodmell DL (1997) Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine 15:892–895
Real LA, Henderson JC, Biek R, Snaman J, Jack TL, Childs JE, Stahl E, Waller L, Tinline R, Nadin-Davis S (2005) Unifying the spatial population dynamics and molecular evolution of epidemic rabies virus. Proc Natl Acad Sci U S A 102:12107–12111
Rotz LD, Hensley JA, Rupprecht CE, Childs JE (1998) Large-scale human exposures to rabid or presumed rabid animals in the United States: 22 cases (1990–1996). J Am Vet Med Assoc 212:1198–1200
Rupprecht CE, Gibbons RV (2004) Clinical practice. Prophylaxis against rabies. N Engl J Med 351:2626–2635
Rupprecht CE, Charlton KM, Artois M, Casey GA, Webster WA, Campbell JB, Lawson KF, Schneider LG (1990) Ineffectiveness and comparative pathogenicity of attenuated rabies virus vaccines for the striped skunk (Mephitis mephitis). J Wildl Dis 26:99–102
Rupprecht CE, Hanlon CA, Cummins LB, Koprowski H (1992) Primate responses to a vaccinia-rabies glycoprotein recombinant virus vaccine. Vaccine 10:368–374
Rupprecht CE, Hanlon CA, Hemachudha T (2002) Rabies re-examined. Lancet Infect Dis 2:327–343
Rupprecht CE, Hanlon CA, Blanton J, Manangan J, Morrill P, Murphy S, Niezgoda M, Orciari LA, Schumacher CL, Dietzschold B (2005) Oral vaccination of dogs with recombinant rabies virus vaccines. Virus Res 111:101–105
Sampath G, Reddy SV, Rao ML, Rao YU, Palaniappan C (2005) An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India. Vaccine 23:897–900
Schumacher CL, Dietzschold B, Ertl HC, Niu HS, Rupprecht CE, Koprowski H (1989) Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies. J Clin Invest 84:971–975
Servat A, Lutsch C, Delore V, Lang J, Veitch K, Cliquet F (2003) Efficacy of rabies immunoglobulins in an experimental post-exposure prophylaxis rodent model. Vaccine 22: 244–249
Shah U, Jaswal GS (1975) Follow-up of rabid dog bite victims. Lancet 2:653–655
Shetty RA, Chaturvedi S, Singh Z (2005) Profile of animal bite cases in Pune. J Commun Dis 37:66–72
Siemoneit K, da Silva Cardoso M, Wolpl A, Koerner K, Subanek B (1994) Isolation and epitope characterization of human monoclonal antibodies to hepatitis C virus core antigen. Hybridoma 13:9–13
Sikes RK, Peacock GV, Acha P, Arko RJ, Dierks R (1971) Rabies vaccines: duration-of-immunity study in dogs. J Am Vet Med Assoc 159:1491–1499
Sitthi-Amorn C, Jiratanavattana V, Keoyoo J, Sonpunya N (1987) The diagnostic properties of laboratory tests for rabies. Int J Epidemiol 16:602–605
Slade HB (1994) Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol 1:613–619
Smith JS, Fishbein DB, Rupprecht CE, Clark K (1991) Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med 324:205–211
Steck F, Wandeler A, Bichsel P, Capt S, Hafliger U, Schneider L (1982) Oral immunization of foxes against rabies. Laboratory and field studies. Comp Immunol Microbiol Infect Dis 5:165–171
Steele JH (1988) Rabies in the Americas and remarks on global aspects. Rev Infect Dis 10 [Suppl 4]:S585–597
Stoger E, Sack M, Nicholson L, Fischer R, Christou P (2005) Recent progress in plantibody technology. Curr Pharm Des 11:2439–2457
Stohr K, Meslin FM (1996) Progress and setbacks in the oral immunisation of foxes against rabies in Europe. Vet Rec 139:32–35
Strady A, Lang J, Rotivel Y, Jaussaud R, Fritzell C, Tsiang H (1996) [Immunoprophylaxis of rabies: current recommendations]. Presse Med 25:1023–1027
Sudarshan MK, Mahendra BJ, Narayan DH (2001) A community survey of dog bites, anti-rabies treatment, rabies and dog population management in Bangalore city. J Commun Dis 33:245–251
Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Ashwath Narayana DH, Abdul Rahman S, Meslin FX, Lobo D, Ravikumar K, Gangaboraiah (2007) Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 11:29–35
Suntharasamai P, Chaiprasithikul P, Wasi C, Supanaranond W, Auewarakul P, Chanthavanich P, Supapochana A, Areeraksa S, Chittamas S, Jittapalapongsa S, et al (1994) A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis. Vaccine 12:508–512
Swaddiwuthipong W, Weniger BG, Wattanasri S, Warrell MJ (1988) A high rate of neurological complications following Semple anti-rabies vaccine. Trans R Soc Trop Med Hyg 82: 472–475
Taylor LH, Latham SM, Woolhouse ME (2001) Risk factors for human disease emergence. Philos Trans R Soc Lond B Biol Sci 356:983–989
Tollis M, Dietzschold B, Volia CB, Koprowski H (1991) Immunization of monkeys with rabies ribonucleoprotein (RNP) confers protective immunity against rabies. Vaccine 9:134–136
Tordo N, Poch O, Ermine A, Keith G, Rougeon F (1986) Walking along the rabies genome: is the large G-L intergenic region a remnant gene? Proc Natl Acad Sci U S A 83:3914–3918
Trabelsi K, Rourou S, Loukil H, Majoul S, Kallel H (2006) Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor. J Biotechnol 121:261–271
Ueki Y, Goldfarb IS, Harindranath N, Gore M, Koprowski H, Notkins AL, Casali P (1990) Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med 171:19–34
Ulmer JB, Liu MA (2002) Ethical issues for vaccines and immunization. Nat Rev Immunol 2:291–296
Velasco-Villa A, Orciari LA, Souza V, Juarez-Islas V, Gomez-Sierra M, Castillo A, Flisser A, Rupprecht CE (2005) Molecular epizootiology of rabies associated with terrestrial carnivores in Mexico. Virus Res 111:13–27
Velasco-Villa A, Orciari LA, Juarez-Islas V, Gomez-Sierra M, Padilla-Medina I, Flisser A, Souza V, Castillo A, Franka R, Escalante-Mane M, Sauri-Gonzalez I, Rupprecht CE (2006) Molecular diversity of rabies viruses associated with bats in Mexico and other countries of the Americas. J Clin Microbiol 44:1697–1710
Wandeler A (2004) Epidemiology and ecology of fox rabies in Europe. In: King AA, Fooks AR, Aubert M, Wandeler A (eds) Historical perspective of rabies in Europe and the Mediterranean basin. OIE, Paris, pp 201–214
Wandeler AI, Budde A, Capt S, Kappeler A, Matter H (1988) Dog ecology and dog rabies control. Rev Infect Dis 10 [Suppl 4]:S684–S688
Wandeler AI, Matter HC, Kappeler A, Budde A (1993) The ecology of dogs and canine rabies: a selective review. Rev Sci Tech 12:51–71
Wang Y, Xiang Z, Pasquini S, Ertl HC (1997) Immune response to neonatal genetic immunization. Virology 228:278–284
Wang Y, Xiang Z, Pasquini S, Ertl HC (1998) Effect of passive immunization or maternally transferred immunity on the antibody response to a genetic vaccine to rabies virus. J Virol 72:1790–1796
Warrell MJ, Nicholson KG, Warrell DA, Suntharasamai P, Chanthavanich P, Viravan C, Sinhaseni A, Chiewbambroongkiat MK, Pouradier-Duteil X, Xueref C, et al (1985) Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1:1059–1062
Whitelam GC, Cockburn W, Owen MR (1994) Antibody production in transgenic plants. Biochem Soc Trans 22:940–944
WHO (1993) Report of the fourth WHO consultation on oral immunization of dogs against rabies. WHO, Geneva. http://www.who.int/rabies/animal/en/whorabres9342.pdf. Cited 18 May 2007
WHO (1996) WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization. WHO, Geneva. http://whqlibdoc.who.int/hq/1996/WHO_EMC_ZOO_96.6.pdf. Cited 18 May 2007
WHO (1998) World survey of rabies N° 32 for the Year 1996. WHO, Geneva. http://whqlibdoc.who.int/hq/1998/WHO_EMC_ZDI_98.4.pdf. Cited 18 May 2007
WHO (2001) Strategies for the control and elimination of rabies in Asia. WHO, Geneva. http://www.who.int/rabies/en/Strategies_for_the_control_and_elimination_of_rabies_in_Asia.pdf. Cited 18 May 2007
WHO (2002a) Rabies vaccines. Wkly Epidemiol Rec 77:109–119
WHO (2002b) World Survey of Rabies N° 35 for the Year 1999. WHO, Geneva. http://www.who.int/rabies/resources/wsr1999/en/index.html. Cited 18 May 2007
WHO (2004) WHO expert consultation on rabies. First report, WHO technical report series 931. WHO, Geneva, p 121
WHO (2006) Rabies fact sheet N° 99. WHO, Geneva. http://www.who.int/mediacentre/factsheets/fs099/en/print.html. Cited 18 May 2007
WHO-APCRI (2004) Assessing burden of rabies in India. WHO, Geneva. http://www.apcri.org/whosurvey.pdf. Cited 18 May 2007
Wiktor TJ, Koprowski H (1978) Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. Proc Natl Acad Sci U S A 75:3938–3942
Wiktor TJ, Sokol F, Kuwert E, Koprowski H (1969) Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin. Proc Soc Exp Biol Med 131:799–805
Wilde H, Choomkasien P, Hemachudha T, Supich C, Chutivongse S (1989) Failure of rabies postexposure treatment in Thailand. Vaccine 7:49–52
Wilde H, Sirikawin S, Sabcharoen A, Kingnate D, Tantawichien T, Harischandra PA, Chaiyabutr N, de Silva DG, Fernando L, Liyanage JB, Sitprija V (1996) Failure of postexposure treatment of rabies in children. Clin Infect Dis 22:228–232
Wilde H, Khawplod P, Hemachudha T, Sitprija V (2002) Postexposure treatment of rabies infection: can it be done without immunoglobulin? Clin Infect Dis 34:477–480
Wilde H, Khawplod P, Khamoltham T, Hemachudha T, Tepsumethanon V, Lumlerdacha B, Mitmoonpitak C, Sitprija V (2005) Rabies control in South and Southeast Asia. Vaccine 23:2284–2289
Willoughby RE Jr, Tieves KS, Hoffman GM, Ghanayem NS, Amlie-Lefond CM, Schwabe MJ, Chusid MJ, Rupprecht CE (2005) Survival after treatment of rabies with induction of coma. N Engl J Med 352:2508–2514
Winkler WG, Bogel K (1992) Control of rabies in wildlife. Sci Am 266:86–92
Wunner WH (2002) Rabies virus. In: Jackson AC, Wunner WH (eds) Rabies. Academic Press, San Diego, pp 23–77
Wunner WH, Larson JK, Dietzschold B, Smith CL (1988) The molecular biology of rabies viruses. Rev Infect Dis 10 [Suppl 4]:S771–S784
Xiang ZQ, Spitalnik S, Tran M, Wunner WH, Cheng J, Ertl HC (1994) Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 199:132–140
Xiang ZQ, Spitalnik SL, Cheng J, Erikson J, Wojczyk B, Ertl HC (1995) Immune responses to nucleic acid vaccines to rabies virus. Virology 209:569–579
Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T, Deka D, Karasev A, Cox S, Randall J, Koprowski H (2002) Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20:3155–3164
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Nagarajan, T., Rupprecht, C.E., Dessain, S.K., Rangarajan, P.N., Thiagarajan, D., Srinivasan, V.A. (2008). Human Monoclonal Antibody and Vaccine Approaches to Prevent Human Rabies. In: Dessain, S.K. (eds) Human Antibody Therapeutics for Viral Disease. Current Topics in Microbiology and Immunology, vol 317. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72146-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-540-72146-8_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-72144-4
Online ISBN: 978-3-540-72146-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)